Citable filing context
EW's research view summarizes recent SEC filing context, starting with management_change from Aug 28, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 28, 2026 | management_change | Donald E. Bobo, Jr., Corporate VP of Strategy and Corporate Development, announced his retirement by mid-year 2027. |
| Jul 23, 2026 | earnings | Edwards Lifesciences reported Q2 2026 sales of $1.74 billion, representing 13.6% growth, and EPS of $0.42. |
| May 8, 2026 | other | Stockholders approved the Amended and Restated Long-Term Stock Incentive Compensation Program and elected directors. |
| Jul 23, 2026 | Guidance: adjusted_eps | 2.95 to 3.05 |
| Jul 23, 2026 | Guidance: adjusted_eps | 0.71 to 0.77 |
| Jul 23, 2026 | Guidance: tavr_sales_growth | 8.00 to 9.00 |
| Aug 4, 2026 | mda_quarterly | Edwards Lifesciences reported strong growth for the first half of 2026, with net sales reaching $3.4 billion, a 15.1% increase year-over-year. This performance was driven by robust demand for its Transcatheter Aortic Valve Replacement (TAVR) platform—specifically the SAPIEN 3 Ultra RESILIA valve—and significant expansion in Transcatheter Mitral and Tricuspid Therapies (TMTT), led by the PASCAL and EVOQUE systems. The company’s financial results reflect a strategic shift following the 2024 divestiture of its Critical Care group. While operating income rose to $990.8 million, net income was impacted by a significant increase in tax expense, which reached 36.4% for the first half of 2026. This spike was primarily due to a $188.2 million valuation allowance following new California tax legislation that limits the utilization of research and development tax credits. Edwards continues to face material tax litigation, including ongoing disputes with the IRS regarding transfer pricing for intercompany royalty transactions. Additionally, the company is actively managing legal challenges related to its PASCAL and SAPIEN 3 Ultra products. Despite these headwinds, the company maintains a solid liquidity position with $3.7 billion in cash and short-term investments, supporting ongoing R&D investments in heart failure management and recent acquisitions like Autus Valve Technologies. |
| May 6, 2026 | mda_quarterly | Net sales increased 16.7% to $1.6 billion for the first quarter of 2026, driven by strong performance in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT). Growth was specifically fueled by the SAPIEN 3 Ultra RESILIA valve, the PASCAL repair system, and the EVOQUE tricuspid valve replacement system, with the most significant regional expansion occurring in Europe. While gross profit rose, margins were pressured by foreign currency fluctuations and manufacturing costs associated with new therapy expansions. Research and development spending increased to support implantable heart failure management. Strategic shifts included the $128.9 million acquisition of Autus Valve Technologies for pediatric pulmonary valves and the divestiture of the Critical Care product group. Financial headwinds include a $123.6 million impairment loss on a VIE investment and potential tax liabilities from ongoing IRS transfer pricing disputes. Furthermore, the company expects approximately $70 million in additional tax expenses in 2026 due to OECD Pillar Two global minimum tax rules. Operational risks persist regarding U.S. trade tariffs and patent litigation involving SAPIEN 3 Ultra and PASCAL products. The company returned $520.1 million to shareholders through common stock repurchases. |
Source: SEC EDGAR filing text and events; period Aug 28, 2026; filed Aug 28, 2026.
EW company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.